Endocrine	endocrine	O	O	O	O
screening	screening	O	O	O	O
in	in	O	O	O	O
1,022	1,022	O	O	O	O
men	men	O	O	O	O
with	with	O	O	O	O
erectile	erectile	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
:	:	O	O	O	O
clinical	clinical	O	O	O	O
significance	significance	O	O	O	O
and	and	O	O	O	O
cost-effective	cost-effective	O	O	O	O
strategy	strategy	O	O	O	O
.	.	O	O	O	O

PURPOSE	purpose	O	O	O	O
:	:	O	O	O	O
We	we	O	O	O	O
reviewed	reviewed	O	O	O	O
the	the	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
serum	serum	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
prolactin	prolactin	O	O	O	O
determination	determination	O	O	O	O
in	in	O	O	O	O
1,022	1,022	O	O	O	O
patients	patients	O	O	O	O
referred	referred	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
erectile	erectile	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
and	and	O	O	O	O
compared	compared	O	O	O	O
the	the	O	O	O	O
data	data	O	O	O	O
with	with	O	O	O	O
history	history	O	O	O	O
,	,	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
physical	physical	O	O	O	O
examination	examination	O	O	O	O
,	,	O	O	O	O
other	other	O	O	O	O
etiological	etiological	O	O	O	O
investigations	investigations	O	O	O	O
and	and	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
endocrine	endocrine	O	O	O	O
therapy	therapy	O	O	O	O
to	to	O	O	O	O
refine	refine	O	O	O	O
the	the	O	O	O	O
rules	rules	O	O	O	O
of	of	O	O	O	O
cost-effective	cost-effective	O	O	O	O
endocrine	endocrine	O	O	O	O
screening	screening	O	O	O	O
and	and	O	O	O	O
to	to	O	O	O	O
pinpoint	pinpoint	O	O	O	O
actual	actual	O	O	O	O
responsibility	responsibility	O	O	O	O
for	for	O	O	O	O
hormonal	hormonal	O	O	O	O
abnormalities	abnormalities	O	O	O	O
.	.	O	O	O	O

MATERIALS	materials	O	O	O	O
AND	and	O	O	O	O
METHODS	methods	O	O	O	O
:	:	O	O	O	O
Testosterone	testosterone	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
prolactin	prolactin	O	O	O	O
were	were	O	O	O	O
determined	determined	O	O	O	O
by	by	O	O	O	O
radioimmunoassay	radioimmunoassay	O	O	O	O
.	.	O	O	O	O

Every	every	O	O	O	O
patient	patient	O	O	O	O
was	was	O	O	O	O
screened	screened	O	O	O	O
for	for	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
451	451	O	O	O	O
were	were	O	O	O	O
screened	screened	O	O	O	O
for	for	O	O	O	O
prolactin	prolactin	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
basis	basis	O	O	O	O
of	of	O	O	O	O
low	low	O	DISEASE	OTHERS	I
sexual	sexual	O	DISEASE	OTHERS	I
desire	desire	O	DISEASE	OTHERS	I
,	,	O	O	O	O
gynecomastia	gynecomastia	O	O	OTHERS	I
or	or	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
less	less	O	O	O	O
than	than	O	O	O	O
4	4	O	O	O	O
ng./ml	ng./ml	O	O	O	O
.	.	O	O	O	O

Determination	determination	O	O	O	O
was	was	O	O	O	O
repeated	repeated	O	O	O	O
in	in	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
abnormal	abnormal	O	O	O	O
first	first	O	O	O	O
results	results	O	O	O	O
.	.	O	O	O	O

Prolactin	prolactin	O	O	O	O
results	results	O	O	O	O
were	were	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
those	those	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
previous	previous	O	O	O	O
personal	personal	O	O	O	O
cohort	cohort	O	O	O	O
of	of	O	O	O	O
1,340	1,340	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
erectile	erectile	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
and	and	O	O	O	O
systematic	systematic	O	O	O	O
prolactin	prolactin	O	O	O	O
determination	determination	O	O	O	O
.	.	O	O	O	O

Main	main	O	O	O	O
clinical	clinical	O	O	O	O
criteria	criteria	O	O	O	O
tested	tested	O	O	O	O
regarding	regarding	O	O	O	O
efficiency	efficiency	O	O	O	O
in	in	O	O	O	O
hormone	hormone	O	O	O	O
determination	determination	O	O	O	O
were	were	O	O	O	O
low	low	O	DISEASE	OTHERS	I
sexual	sexual	O	DISEASE	OTHERS	I
desire	desire	O	DISEASE	OTHERS	I
,	,	O	O	O	O
small	small	O	O	O	O
testes	testes	O	O	O	O
and	and	O	O	O	O
gynecomastia	gynecomastia	O	O	OTHERS	I
.	.	O	O	O	O

Endocrine	endocrine	O	O	O	O
therapy	therapy	O	O	O	O
consisted	consisted	O	O	O	O
of	of	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
heptylate	heptylate	O	O	OTHERS	I
or	or	O	O	O	O
human	human	CHEMICALS	O	OTHERS	I
chorionic	chorionic	CHEMICALS	O	OTHERS	I
gonadotropin	gonadotropin	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
hypogonadism	hypogonadism	O	O	OTHERS	I
and	and	O	O	O	O
bromocriptine	bromocriptine	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Testosterone	testosterone	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
less	less	O	O	O	O
than	than	O	O	O	O
3	3	O	O	O	O
ng./ml	ng./ml	O	O	O	O
.	.	O	O	O	O

in	in	O	O	O	O
107	107	O	O	O	O
patients	patients	O	O	O	O
but	but	O	O	O	O
normal	normal	O	O	O	O
in	in	O	O	O	O
40	40	O	O	O	O
%	%	O	O	O	O
at	at	O	O	O	O
repeat	repeat	O	O	O	O
determination	determination	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
prevalence	prevalence	O	O	O	O
of	of	O	O	O	O
repeatedly	repeatedly	O	O	O	O
low	low	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
increased	increased	O	O	O	O
with	with	O	O	O	O
age	age	O	O	O	O
(	(	O	O	O	O
4	4	O	O	O	O
%	%	O	O	O	O
before	before	O	O	O	O
age	age	O	O	O	O
50	50	O	O	O	O
years	years	O	O	O	O
and	and	O	O	O	O
9	9	O	O	O	O
%	%	O	O	O	O
50	50	O	O	O	O
years	years	O	O	O	O
or	or	O	O	O	O
older	older	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Two	two	O	O	O	O
pituitary	pituitary	O	O	OTHERS	I
tumors	tumors	O	DISEASE	OTHERS	I
were	were	O	O	O	O
discovered	discovered	O	O	O	O
after	after	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
determination	determination	O	O	O	O
.	.	O	O	O	O

Most	most	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
low	low	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
seemed	seemed	O	O	O	O
to	to	O	O	O	O
result	result	O	O	O	O
from	from	O	O	O	O
nonorganic	nonorganic	O	O	O	O
hypothalamic	hypothalamic	O	O	OTHERS	I
dysfunction	dysfunction	O	O	OTHERS	I
because	because	O	O	O	O
of	of	O	O	O	O
normal	normal	O	O	O	O
serum	serum	O	O	O	O
luteinizing	luteinizing	CHEMICALS	O	OTHERS	I
hormone	hormone	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
prolactin	prolactin	O	O	O	O
and	and	O	O	O	O
to	to	O	O	O	O
have	have	O	O	O	O
only	only	O	O	O	O
a	a	O	O	O	O
small	small	O	O	O	O
role	role	O	O	O	O
in	in	O	O	O	O
erectile	erectile	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
(	(	O	O	O	O
definite	definite	O	O	O	O
improvement	improvement	O	O	O	O
in	in	O	O	O	O
only	only	O	O	O	O
16	16	O	O	O	O
of	of	O	O	O	O
44	44	O	O	O	O
[	[	O	O	O	O
36	36	O	O	O	O
%	%	O	O	O	O
]	]	O	O	O	O
after	after	O	O	O	O
androgen	androgen	O	O	OTHERS	I
therapy	therapy	O	O	O	O
,	,	O	O	O	O
normal	normal	O	O	O	O
morning	morning	O	O	O	O
or	or	O	O	O	O
nocturnal	nocturnal	O	O	O	O
erections	erections	O	O	O	O
in	in	O	O	O	O
30	30	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
definite	definite	O	O	O	O
vasculogenic	vasculogenic	O	O	O	O
contributions	contributions	O	O	O	O
in	in	O	O	O	O
42	42	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Determining	determining	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
only	only	O	O	O	O
in	in	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
low	low	O	DISEASE	OTHERS	I
sexual	sexual	O	DISEASE	OTHERS	I
desire	desire	O	DISEASE	OTHERS	I
or	or	O	O	O	O
abnormal	abnormal	O	O	O	O
physical	physical	O	O	O	O
examination	examination	O	O	O	O
would	would	O	O	O	O
have	have	O	O	O	O
missed	missed	O	O	O	O
40	40	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
cases	cases	O	O	O	O
with	with	O	O	O	O
low	low	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
including	including	O	O	O	O
37	37	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
those	those	O	O	O	O
subsequently	subsequently	O	O	O	O
improved	improved	O	O	O	O
by	by	O	O	O	O
androgen	androgen	O	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

Prolactin	prolactin	O	O	O	O
exceeded	exceeded	O	O	O	O
20	20	O	O	O	O
ng./ml	ng./ml	O	O	O	O
.	.	O	O	O	O

in	in	O	O	O	O
5	5	O	O	O	O
men	men	O	O	O	O
and	and	O	O	O	O
was	was	O	O	O	O
normal	normal	O	O	O	O
in	in	O	O	O	O
2	2	O	O	O	O
at	at	O	O	O	O
repeat	repeat	O	O	O	O
determination	determination	O	O	O	O
.	.	O	O	O	O

Only	only	O	O	O	O
1	1	O	O	O	O
prolactinoma	prolactinoma	O	DISEASE	OTHERS	I
was	was	O	O	O	O
discovered	discovered	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
data	data	O	O	O	O
are	are	O	O	O	O
lower	lower	O	O	O	O
than	than	O	O	O	O
those	those	O	O	O	O
we	we	O	O	O	O
found	found	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
last	last	O	O	O	O
2	2	O	O	O	O
decades	decades	O	O	O	O
(	(	O	O	O	O
overall	overall	O	O	O	O
prolactin	prolactin	O	O	O	O
greater	greater	O	O	O	O
than	than	O	O	O	O
20	20	O	O	O	O
ng./ml	ng./ml	O	O	O	O
.	.	O	O	O	O

in	in	O	O	O	O
1.86	1.86	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
1,821	1,821	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
prolactinomas	prolactinomas	O	O	OTHERS	I
in	in	O	O	O	O
7	7	O	O	O	O
,	,	O	O	O	O
0.38	0.38	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Bromocriptine	bromocriptine	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
definitely	definitely	O	O	O	O
effective	effective	O	O	O	O
in	in	O	O	O	O
cases	cases	O	O	O	O
with	with	O	O	O	O
prolactin	prolactin	O	O	O	O
greater	greater	O	O	O	O
than	than	O	O	O	O
35	35	O	O	O	O
ng./ml	ng./ml	O	O	O	O
.	.	O	O	O	O

(	(	O	O	O	O
8	8	O	O	O	O
of	of	O	O	O	O
12	12	O	O	O	O
compared	compared	O	O	O	O
to	to	O	O	O	O
only	only	O	O	O	O
9	9	O	O	O	O
of	of	O	O	O	O
22	22	O	O	O	O
cases	cases	O	O	O	O
with	with	O	O	O	O
prolactin	prolactin	O	O	O	O
between	between	O	O	O	O
20	20	O	O	O	O
and	and	O	O	O	O
35	35	O	O	O	O
ng./ml	ng./ml	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Testosterone	testosterone	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
low	low	O	O	O	O
in	in	O	O	O	O
less	less	O	O	O	O
than	than	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
cases	cases	O	O	O	O
with	with	O	O	O	O
prolactin	prolactin	O	O	O	O
greater	greater	O	O	O	O
than	than	O	O	O	O
35	35	O	O	O	O
ng./ml	ng./ml	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Low	low	O	O	O	O
prevalences	prevalences	O	O	O	O
and	and	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
low	low	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
high	high	O	O	O	O
prolactin	prolactin	O	O	O	O
in	in	O	O	O	O
erectile	erectile	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
can	can	O	O	O	O
not	not	O	O	O	O
justify	justify	O	O	O	O
their	their	O	O	O	O
routine	routine	O	O	O	O
determination	determination	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
cost-effective	cost-effective	O	O	O	O
screening	screening	O	O	O	O
strategies	strategies	O	O	O	O
recommended	recommended	O	O	O	O
so	so	O	O	O	O
far	far	O	O	O	O
missed	missed	O	O	O	O
40	40	O	O	O	O
to	to	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
cases	cases	O	O	O	O
improved	improved	O	O	O	O
with	with	O	O	O	O
endocrine	endocrine	O	O	O	O
therapy	therapy	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
pituitary	pituitary	O	O	OTHERS	I
tumors	tumors	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
now	now	O	O	O	O
advocate	advocate	O	O	O	O
that	that	O	O	O	O
before	before	O	O	O	O
age	age	O	O	O	O
50	50	O	O	O	O
years	years	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
be	be	O	O	O	O
determined	determined	O	O	O	O
only	only	O	O	O	O
in	in	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
low	low	O	DISEASE	OTHERS	I
sexual	sexual	O	DISEASE	OTHERS	I
desire	desire	O	DISEASE	OTHERS	I
and	and	O	O	O	O
abnormal	abnormal	O	O	O	O
physical	physical	O	O	O	O
examination	examination	O	O	O	O
but	but	O	O	O	O
that	that	O	O	O	O
it	it	O	O	O	O
be	be	O	O	O	O
measured	measured	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
men	men	O	O	O	O
older	older	O	O	O	O
than	than	O	O	O	O
50	50	O	O	O	O
years	years	O	O	O	O
.	.	O	O	O	O

Prolactin	prolactin	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
determined	determined	O	O	O	O
only	only	O	O	O	O
in	in	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
low	low	O	DISEASE	OTHERS	I
sexual	sexual	O	DISEASE	OTHERS	I
desire	desire	O	DISEASE	OTHERS	I
,	,	O	O	O	O
gynecomastia	gynecomastia	O	O	OTHERS	I
and/or	and/or	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
less	less	O	O	O	O
than	than	O	O	O	O
4	4	O	O	O	O
ng./ml	ng./ml	O	O	O	O
.	.	O	O	O	O

